Followers | 145 |
Posts | 27561 |
Boards Moderated | 3 |
Alias Born | 02/07/2004 |
Friday, February 10, 2006 9:08:34 AM
Thursday February 9, 4:19 pm ET
YOKNEAM, ISRAEL--(MARKET WIRE)--Feb 9, 2006 -- Syneron Medical Ltd. (NasdaqNM:ELOS - News), an innovator in the development, marketing and sales of elos™ combined-energy medical aesthetic devices, today announced the appointment of David Seligman as its Chief Financial Officer.
Prior to joining Syneron, Mr. Seligman, 47, was Chief Financial Officer for several public companies traded on NASDAQ. Mr. Seligman served as CFO of RADVISION, where he took part in its very successful initial public offering, and as CFO of LanOptics. In his most recent position, Mr. Seligman served as CFO of NUR Macroprinters where he took part in designing and implementing the financial initiatives which contributed to the company's turnaround. Mr. Seligman has also held several other financial positions in hi-tech companies in the US and Israel. Mr. Seligman has a B.A. in Political Science and Geography and an M.B.A. in Accounting and Finance from Tel Aviv University.
David Schlachet commented: "David's highly respected credibility within the financial community and his strong business background makes him well-suited to become part of Syneron's senior management. We look forward to the contributions he will make as he joins Syneron and leads our financial team worldwide."
About Syneron
Syneron Medical Ltd. (NasdaqNM:ELOS - News) develops, manufactures and distributes medical aesthetic devices that are powered by elos™, the combined-energy technology of bi-polar radio frequency and light. The company's innovative elos technology provides the foundation for highly effective, safe and cost-effective systems that enable physicians to provide advanced solutions for a broad range of medical-aesthetic applications including hair removal, wrinkle reduction, rejuvenating the skin's appearance through the treatment of superficial benign vascular and pigmented lesions, and the treatment of acne, leg veins and cellulite. Founded in 2000, the corporate, R&D, and manufacturing headquarters for Syneron Medical Ltd. are located in Israel. Syneron has offices and distributors throughout the world, including North American Headquarters in Canada, European Headquarters in Germany, and Asia-Pacific Headquarters in Hong Kong, which provide sales, service and support. Additional information can be found at www.syneron.com.
http://biz.yahoo.com/iw/060209/0109235.html
Dubi
NanoViricides Reports that the Phase I NV-387 Clinical Trial is Completed Successfully and Data Lock is Expected Soon • NNVC • May 2, 2024 10:07 AM
ILUS Files Form 10-K and Provides Shareholder Update • ILUS • May 2, 2024 8:52 AM
Avant Technologies Names New CEO Following Acquisition of Healthcare Technology and Data Integration Firm • AVAI • May 2, 2024 8:00 AM
Bantec Engaged in a Letter of Intent to Acquire a Small New Jersey Based Manufacturing Company • BANT • May 1, 2024 10:00 AM
Cannabix Technologies to Deliver Breath Logix Alcohol Screening Device to Australia • BLO • Apr 30, 2024 8:53 AM
Hydromer, Inc. Reports Preliminary Unaudited Financial Results for First Quarter 2024 • HYDI • Apr 29, 2024 9:10 AM